glp-1 agonists and retained gastric contents at endoscopy American Society for Gastrointestinal position statement on periendoscopic management of patients on glucagon-like peptide-1 receptor sodium-glucose cotransporter-2 inhibitors Glucagon-like peptide-1 receptor agonists before
Description
GLP-1R agonist 2 has the potential for research in metabolic diseases such as type 2 diabetes and obesity

The mechanisms underlying these effects involve the modulation of signaling pathways associated with cell growth, survival, and metabolism

Compare Jardiance vs Ozempic for type 2 diabetes and weight loss

Both glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 (SGLT-2) inhibitors can reduce CV risk in patients with T2D, and both are recommended by the American Diabetes Association to reduce the risk of major cardiovascular events (MACE)

As the number of diabetic patien...

Always follow your providers guidance and reach out with any questions or concerns
